← Back to Search

Janus Kinase (JAK) Inhibitor

Ruxolitinib cream for Atopic Dermatitis

Phase 1
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, weeks 2, 4 and 8
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a cream called ruxolitinib on children with atopic dermatitis, a condition that makes their skin itchy and inflamed. The cream is applied regularly to see if it is safe and effective. It works by reducing inflammation and calming the immune system's response in the skin.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, weeks 2, 4 and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, weeks 2, 4 and 8 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of treatment-emergent adverse events
Secondary study objectives
Accumulation ratio of Ruxilitinib
Plasma Css of Ruxolitinib

Side effects data

From 2021 Phase 3 trial • 330 Patients • NCT04052425
1%
Tibia fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vehicle Cream BID
Ruxolitinib Cream 1.5% BID

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ruxolitinib creamExperimental Treatment1 Intervention
ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib cream
2022
Completed Phase 3
~1850

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
391 Previous Clinical Trials
63,806 Total Patients Enrolled
Innovaderm ResearchUNKNOWN
1 Previous Clinical Trials
40 Total Patients Enrolled
Haq Nawaz, MD, MPH, MBA, MSStudy DirectorIncyte Corporation
~7 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top